Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission

Helping Babies with HIV Get the Strongest Start Possible
This study is exploring whether starting HIV treatment very early in life can help babies control the virus and possibly reach remission. If your child may be eligible, you can take a short questionnaire to learn more and see if this study could be a fit for your family.

Am I Eligible?

How it works?

This study looks at how early, intensive HIV treatment works in infants diagnosed with HIV. Babies in the study receive a combination of HIV medications soon after birth. Some may also receive an additional antibody treatment designed to help the body fight the virus.

Over time, doctors will monitor how well the treatment controls HIV. For some children, treatment may be safely paused under close supervision to see if the virus stays under control without medication. If the virus returns, treatment will be restarted right away.

Call +1-910-000-0984

now to find out if you are eligible

Call Now

Explore whether this study could be a fit for your family

Complete a short questionnaire to help us understand if your child may qualify for this research study. If they’re a match, we’ll guide you through the next steps.

Start Answering

Check if you are eligible Enter contact details

Are you a mother with EITHER Presumed HIV infection defined as at least one positive rapid HIV antibody-based test result from a sample collected in the peripartum period. Presumed infection must be confirmed within 10 business days of enrollment OR Confirmed HIV infection defined as positive results from two samples collected at different timepoints

Have you been diagnosed with HIV in the past or have a confirmed diagnosis more than 10 days of study enrollment?

Yes No

Preview complete

The prescreener preview is complete. You may now close the preview.

Get in touch

Contact the Diabetes Clinical Research Study screening center to find out if you may be eligible to participate.

1800 443 6547

Email: Study@Trialx.com

Your journey

Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Duis viverra et felis

Receiving the medication

You would receive entanercept (Enbrel) twice a week for 12 weeks and then once a week for 12 weeks. Etanercept as well as study related medical care is provided at no cost.

Visiting the study site

Study participation involves approximately 8 visits to your local study center over 6 to 7 months.

Follow-up

There would also be a follow-up telephone call 30 days after completing the study. No visits are required after participation is complete.

Call +1-910-000-0984

now to find out if you are eligible

Call Now